Reports Q2 revenue $114.3M, consensus $98.97M. Cash was $362.8M as of June 30, 2024 vs. $350.2M as of March 31, 2024.”We set a new high-water mark for the business in the second quarter of 2024, with product and service revenue growth driven by the sustained momentum of OCS NOP and our transplant logistics network,” said CEO Waleed Hassanein. “We remain well positioned to successfully execute our 2024 strategy and to launch our new OCS lung and heart clinical programs in 2025.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: